Mayo Clinic Consensus Recommendations for the Depth of Excision in Primary Cutaneous Melanoma
- â€œRosary of Testesâ€: Splenogonadal Fusion in Association with Bilateral Abdominal Testes Presenting as Polyorchidism. Shadpour, Pejman; Rezaimehr, Behkam // Case Reports in Urology;11/29/2015, p1
Polyorchidism is a rare anomaly where early segmentation in the gonadal ridge can lead to the development of three or less commonly four testes in one individual. Just over 150 reports of this phenomenon exist in English medical literature. However, once confronted by the clinical finding of...
- Therapy Moves to Phase III. Reiman, Patty // Dermatology Times;Feb2003, Vol. 24 Issue 2, p24
Focuses on the results of the clinical trial conducted on the effectiveness of a combination vaccine used to treat metastatic melanoma in Detroit, Michigan. Comparison between biochemotherapy and immunotherapy; Importance of melacine in promoting prolonged disease stability; Combination of...
- What can we learn from phase II adjuvant trials in melanoma? Keilholz, U; Suciu, S; Eggermont, A M M // British Journal of Cancer;7/1/2000, Vol. 83 Issue 1, p6
Editorial. Focuses on the study related to clinical trial of treatment of melanoma patients in second and fourth stages. Situation at the time the trial was instituted; Type of conclusions that is possible from an adjuvant non-randomized phase second clinical trial; Things that can be learnt...
- Melanoma targets. // Nature Reviews Cancer;Jul2011, Vol. 11 Issue 7, p463
The article discusses three clinical trials for enhancing the treatment of melanoma.
- Research & Markets: Melanoma Global Clinical Trials Review Q4 2010. // Biomedical Market Newsletter;3/31/2011, p603
The article reports on the addition of GlobalData's new report titled "Melanoma Global Clinical Trials Review, Q4 2010" which provides information and data concerning on the clinical trials on melanoma.
- Shorter, high-dose interferon regimen feasible for stage III melanoma patients. McKnight, Whitney; Cowles, Carey // Hem/Onc Today;8/10/2011, Vol. 12 Issue 15, p1
The article reports on the results of a clinical trial presented by Vanna Chiarion-Sileni at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois which indicate that a shorter, high-dose interferon regime is feasible for stage III melanoma patients.
- Immunotherapeutic did not meet co-primary endpoint in study. // Hem/Onc Today;11/25/2013, Vol. 14 Issue 22, p64
The article focuses on the announcement by healthcare company GlaxoSmithkline that its phase 3 trial which evaluated the efficacy and safety of the protein melanoma-associated antigen-A3 (MAGE-A3) immunotherapeutic did not meet its first co-primary endpoint of significantly extending...
- G 3139: Augmerosen, Bcl-2 Antisense Oligonucleotide - Genta, GC 3139, Genasense. // Drugs in R&D;2002, Vol. 3 Issue 1, p44
Adis CommentsG 3139 [GC 3139; Genasenseâ„¢, BCL2 antisense oligonucleotide, augmerosen] is an antisense oligonucleotide developed by Genta in the USA. It is targeted towards the Bcl-2 protein, which is a potent inhibitor of apoptosis and is overexpressed in many cancers including, follicular...
- Melanoma vaccines show promise. Josefson, Deborah // BMJ: British Medical Journal (International Edition);03/14/98, Vol. 316 Issue 7134, p800
Details the clinical trials for vaccines developed to fight melanoma. Procedure used in the trials; Findings of the trials.